- Conditions
- Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
- Interventions
- nebulized ketamine, nebulized midazolam
- Drug
- Lead sponsor
- Theresa Jacob, PhD, MPH
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 1:37 AM EDT